USFDA nod for Cortrophin Gel to treat Autoimmune Disorders

With the FDA approval of Cortrophin gel, patients will now have a significant new treatment option.”

Picture: Pixabay

Last Updated on November 4, 2021 by The Health Master

ANI Pharmaceuticals, Inc. announced that the US Food and Drug Administration (USFDA) has approved the company’s supplemental New Drug Application (sNDA) for Purified Cortrophin gel (Repository Corticotropin Injection USP) (Cortrophin gel).

This drug is used for the treatment of certain chronic autoimmune disorders, including acute exacerbations of multiple sclerosis (MS) and rheumatoid arthritis (RA), in addition to excess urinary protein due to nephrotic syndrome.

Cortrophin gel is an adrenocorticotropic hormone (ACTH), also known as purified corticotropin.

USFDA’s approval of Cortrophin gel enables us to bring a much-needed treatment choice to patients with acute exacerbations of multiple sclerosis and rheumatoid arthritis as well as nephrotic syndrome, who are coping with a devastating disease on a daily basis,” said Nikhil Lalwani, president and chief executive officer of ANI Pharmaceuticals.

“We are pleased to offer Cortrophin gel, an established treatment, to provide another option to patients and prescribers.

This approval reflects ANI’s commitment to the patients and physicians we serve, combined with US-based development and manufacturing. We anticipate a full-scale commercial launch by early in the first quarter of 2022.”

“Patients who are refractory or intolerant to corticosteroids have an especially urgent need for effective alternatives and are at risk of ongoing organ damage with long-term disease,” said Mary Pao Seideman, MD, PhD, chief medical officer of ANI Pharmaceuticals. “For over 30 years, there has only been one available treatment in the ACTH category.

With the USFDA approval of Cortrophin gel, patients will now have a significant new treatment option.”

Cortrophin gel was first approved in 1954 and used for decades to treat certain chronic autoimmune disorders. ANI acquired the NDA for Cortrophin Gel from Merck & Co. in 2016. The company has made a significant investment over the past five years in establishing and updating manufacturing processes and ensuring a sustainable, U.S.-based supply chain.

ANI submitted an sNDA to the USFDA in June 2021 to bring Cortrophin gel back to market for patients, physicians and an overall healthcare system in need of greater access to ACTH therapies.

As part of its commitment to ensuring optimal access to Cortrophin Gel, ANI is investing in and will launch a patient support program including financial assistance such as copay cards, for eligible patients. Additional details on the program will be provided in conjunction with the commercial launch.

ANI Pharmaceuticals is a diversified bio-pharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need.

Allergan gets USFDA nod for eye drop to treat blurry vision

Novartis gets USFDA approval for drug to treat Chronic Leukemia

Aurobindo Pharma gets USFDA nod for cancer treatment drug

USFDA approves drug for severe Itching in kidney disease patients

Zydus Cadila gets USFDA nod for Tofacitinib ER Tablets

WHO approves Indian Firm Bharat Biotech’s Covaxin

There is need for clear definition of excipients and its GMP:…

FDA cancels licenses of 2 Blood Cantres, suspends 12 firms

Duties of Retail Chemists / Medical Store / Pharmacy

Compound that can potentially ease COVID-19 symptoms identified

Govt to plan to conduct these 8 studies on Pharma & Medical Devices

Govt to amend New Drugs & Clinical Trials Rules

Govt takes important decisions on Pharma & Medical Devices Industry

Govt releases draft policy for R&D, Pharma and Medical Devices

Latest Notifications regarding Pharmaceuticals

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon
YouTube Icon

Enter your email address:

Delivered by FeedBurner